Patents Assigned to G2B PHARMA INC.
  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20210069126
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 11, 2021
    Applicant: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal formulation of epinephrine for the treatment of anaphylaxis
    Patent number: 10806709
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: October 20, 2020
    Assignee: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20170368000
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 28, 2017
    Applicant: G2B Pharma Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal formulation of epinephrine for the treatment of anaphylaxis
    Patent number: 9789071
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 17, 2017
    Assignee: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
    Publication number: 20160220489
    Abstract: Disclosed herein are dry powder compositions and unit doses that comprise vasoactive agents, and/or anti-anaphylactic and/or anti-anaphylactoid agents suitable for intranasal administration, methods of making the compositions, and methods of using the compositions to treat disorders, for example anaphylaxis, anaphylactoid reactions, bronchospasm, cardiac arrest, hypotensive shock, or other situations requiring the need to implement cardiopulmonary resuscitation (CPR) and/or basic or advanced cardiac life support (ACLS).
    Type: Application
    Filed: September 2, 2014
    Publication date: August 4, 2016
    Applicant: G2B Pharma Inc.
    Inventors: Nigel T. Fleming, Shunji Haruta
  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20150005356
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 1, 2015
    Applicant: G2B PHARMA INC.
    Inventor: Nigel Ten Fleming